FDA Steps Up Effort to Restrict Conflicts on Advisory Panels

The FDA is proposing to disclose a new detail in listing conflicts of interest for advisory committee members — the name of the company or institution involved — as the agency’s head recommends that officials minimize conflicts of interest on panels. At present, the agency discloses only whether a panel member’s financial interest is associated with the sponsor, a competitor or another affected company. The new recommendations are included in a draft guidance. Comments are due June 21.
Devices & Diagnostics Letter